Clinical trialNCT05939414RecruitingPhase 3Interventional

An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.

SponsorNovartis PharmaceuticalsEnrollment450Oligometastatic Prostate Cancer (OMPC)

View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Novartis Pharmaceuticals
Novartis Pharmaceuticals
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

147 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Argentina

Novartis Investigative Site
CABA, Buenos Aires, Argentina
Recruiting
Novartis Investigative Site
CABA, Argentina
Recruiting
Novartis Investigative Site
Caba, Argentina
Recruiting

Australia

Novartis Investigative Site
Darlinghurst, New South Wales, Australia
Recruiting
Novartis Investigative Site
Herston, Queensland, Australia
Recruiting
Novartis Investigative Site
Adelaide, South Australia, Australia
Recruiting
Novartis Investigative Site
Malvern, Victoria, Australia
Recruiting

Austria

Novartis Investigative Site
Linz, Austria
Recruiting
Novartis Investigative Site
Vienna, Austria
Recruiting

Belgium

Novartis Investigative Site
Aalst, Belgium
Recruiting
Novartis Investigative Site
Ghent, Belgium
Recruiting
Novartis Investigative Site
Wilrijk, Belgium
Recruiting

Brazil

Novartis Investigative Site
São Paulo, São Paulo, Brazil
Recruiting

Canada

Novartis Investigative Site
Calgary, Alberta, Canada
Recruiting
Novartis Investigative Site
Halifax, Nova Scotia, Canada
Recruiting
Novartis Investigative Site
London, Ontario, Canada
Recruiting
Novartis Investigative Site
Ottawa, Ontario, Canada
Recruiting
Novartis Investigative Site
Toronto, Ontario, Canada
Recruiting
Novartis Investigative Site
Montreal, Quebec, Canada
Recruiting
Novartis Investigative Site
Montreal, Quebec, Canada
Recruiting
Novartis Investigative Site
Québec, Quebec, Canada
Recruiting

China

Novartis Investigative Site
Beijing, China
Recruiting
Novartis Investigative Site
Guangzhou, China
Recruiting
Novartis Investigative Site
Shanghai, China
Recruiting

Colombia

Novartis Investigative Site
Bogota, Cundinamarca, Colombia
Recruiting
Novartis Investigative Site
Bogotá, Colombia
Recruiting

Czechia

Novartis Investigative Site
Ostrava, Poruba, Czechia
Recruiting
Novartis Investigative Site
Olomouc, Czechia
Recruiting
Novartis Investigative Site
Prague, Czechia
Recruiting

France

Novartis Investigative Site
Saint-Cloud, Hauts De Seine, France
Recruiting
Novartis Investigative Site
Angers, France
Recruiting
Novartis Investigative Site
Bordeaux, France
Recruiting
Novartis Investigative Site
Bron, France
Recruiting
Novartis Investigative Site
Clermont-Ferrand, France
Recruiting
Novartis Investigative Site
Rouen, France
Recruiting
Novartis Investigative Site
Saint-Herblain, France
Recruiting

Germany

Novartis Investigative Site
Munich, Bavaria, Germany
Recruiting
Novartis Investigative Site
Cologne, North Rhine-Westphalia, Germany
Recruiting
Novartis Investigative Site
Aachen, Germany
Recruiting
Novartis Investigative Site
Augsburg, Germany
Recruiting

107 more sites on the registry record.ClinicalTrials.gov ↗

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Vipivotide tetraxetan →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 12 Mar 2024
Primary completion: 25 Apr 2028
Completion: 3 Oct 2031
Last update posted: 10 Jun 2026
Registered enrollment: 450
Registry id: NCT05939414

Cross-registrations

EU-CTR / CTIS (EudraCT)2022-502956-29-00

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.